Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PDS Biotechnology Q1 Earnings Call Highlights
02:11pm, Wednesday, 13'th May 2026
PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and r
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
10:10am, Wednesday, 13'th May 2026
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
07:00am, Wednesday, 13'th May 2026
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunoth
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
08:00am, Wednesday, 06'th May 2026
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
12:02pm, Monday, 30'th Mar 2026
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
04:05pm, Tuesday, 24'th Mar 2026
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Ne
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
08:45am, Thursday, 22'nd Jan 2026
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years Patent Enhances IP Estate for Lead Asset; Combined with Anticipated B
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
08:45am, Friday, 09'th Jan 2026
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEW
PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened
01:51am, Wednesday, 17'th Dec 2025
PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) traded down 1.9% during trading on Tuesday. The stock traded as low as $0.8746 and last traded at $0.9010. 355,481 shares changed hands d
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
08:00am, Tuesday, 09'th Dec 2025
New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINC
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
01:01pm, Monday, 08'th Dec 2025
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
